The I²NM² is a University of Missouri research center dedicated to the discovery and application of fundamental and translational medical science based upon previously unexplored chemistry combined with nanotechnology and the biosciences. The I²NM² has become an international leader in the reinvigorated field of boron neutron capture therapy (BNCT), a cell-selective binary radiation method for cancer, arthritis and evolving non-invasive surgical protocols. The BNCT program is being conducted with a dedicated neutron source at the University of Missouri Research Reactor (MURR; the most powerful university-based research reactor in the world) and the use of the life sciences laboratory of the Dalton Cardiovascular Research Center, including small animal facilities. The I²NM² is housed in its own 30,000 ft² laboratory building in Reactor Park adjacent to the MURR and the Dalton Cardiovascular Research Center.
The I²NM² is engaged in multifaceted research projects involving the creation of novel materials, devices and agents enhanced by nanotechnology with applications in medicine, related materials science and beyond.
The unique strength of the I²NM² is its new approach to medical inventions and its developing position as the strongest research facility for the development of boron neutron capture therapy of cancer in the world. These efforts are supported by superbly equipped laboratories with great strength in chemical synthesis coupled with nanotechnology, biological chemistry, radiation biology and medicine. The I²NM² is truly dedicated to translational medicine.
The I²NM² is currently staffed by six faculty and four adjunct faculty in chemistry, anesthesiology, veterinary medicine and radiation biology. A research team of approximately sixteen researchers is currently employed. The Institute has been funded by the NIH, DOE, NSF, Honeywell and the Washington Savannah River Company.